本页面由Tiger Trade Technology Pte. Ltd.提供服务

奥麦罗制药

12.54
+0.29002.37%
盘后12.42-0.1200-0.96%19:08 EDT
成交量:109.20万
成交额:1,360.32万
市值:9.03亿
市盈率:-250.80
高:12.60
开:12.48
低:12.09
收:12.25
52周最高:17.65
52周最低:2.95
股本:7,199.62万
流通股本:6,928.40万
量比:1.10
换手率:1.58%
股息:- -
股息率:- -
每股收益(TTM):-0.0500
每股收益(LYR):-0.0527
净资产收益率:-576.33%
总资产收益率:-25.47%
市净率:-7.45
市盈率(LYR):-237.74

数据加载中...

公司资料

公司名字:
奥麦罗制药
交易所:
NASDAQ
成立时间:
1994
员工人数:
175
公司地址:
The Omeros Building,201 Elliott Avenue West,Seattle,Washington,United States
邮编:
98119
电话:
传真:
- -
简介:
Omeros Corporation在华盛顿成立。该公司正在推进多个开发项目,重点关注与补体系统相关的疾病和紊乱,补体系统是一组专门的蛋白质,可防止侵袭性病原体以及体内受损细胞,是人体免疫系统的重要组成部分。当触发时,补体的各种成分协同产生免疫反应,对抗感染并清除受损或死亡的细胞,维持身体系统的健康功能。然而,补体系统的失调(即过度激活或激活不足)可能是有害的,并且与感染和非感染性疾病的脆弱性增加有关,包括自身免疫性疾病、慢性炎症、血栓性微血管病和癌症。

董事

名称
职位
Gregory A. Demopulos
President, Chief Executive Officer and Chairman of the Board
Arnold C. Hanish
Independent Director
Diana T. Perkinson
Independent Director
Leroy E. Hood
Independent Director
Peter A. Demopulos
Independent Director
Rajiv Shah
Independent Director
Thomas F. Bumol
Independent Director
Thomas J. Cable
Independent Director

股东

名称
职位
Gregory A. Demopulos
President, Chief Executive Officer and Chairman of the Board
Andreas Grauer
Chief Medical Officer and Vice President
Catherine A. Melfi
Chief Regulatory Officer and Vice President, Regulatory Affairs & Quality Systems
David J. Borges
Vice President, Finance, Chief Accounting Officer and Treasurer
David W. Ghesquiere
Vice President, Chief Business Development Officer
George A. Gaitanaris
Vice President, Science and Chief Scientific Officer
J. Steven Whitaker
Vice President, Clinical Development
Mariana N. Dimitrova
Vice President, Chemistry, Manufacturing and Controls
Nadia Dac
Chief Commercial Officer and Vice President
Peter B. Cancelmo
Vice President, General Counsel and Secretary
Peter W. Williams
Vice President, Human Resources